






University of Kwazulu-Natal 
 
 
Title: The impact of the introduction of direct first and second-line reflex 
testing in the management of drug-resistant Tuberculosis at Greytown 








College of Health Sciences 
School of Laboratory Medicine and Medical Science 















Title: The impact of the introduction of direct first and second-line reflex 
testing in the management of drug-resistant Tuberculosis at Greytown 








Submitted in fulfilment of the requirements for the degree of Master of Medical Science (Medical 




In the College of Health Sciences 




Supervisor: Professor Koleka Mlisana 








This study was undertaken to assess the value and effectiveness of the changes in tuberculosis 
diagnostics in South Africa. The research is of importance in the field of medical microbiology and 
public health and aimed to provide previously unknown data that will aid stakeholders in decision-




































 I ................................................................................ declare that 
 (i) The research reported in this dissertation/thesis, except where otherwise indicated, is my 
original research. 
 
 (ii) This dissertation/thesis has not been submitted for any degree or examination at any other 
university. 
 
 (iii) This dissertation/thesis does not contain other persons’ data, pictures, graphs or other 
information, unless specifically acknowledged as being sourced from other persons. 
 
 (iv) This dissertation/thesis does not contain other persons’ writing, unless specifically 
acknowledged as being sourced from other researchers. Where other written sources have 
been quoted, then: 
  a) their words have been re-written, but the general information attributed to them has 
been referenced; 
  b) where their exact words have been used, their writing has been placed inside quotation 
marks, and referenced. 
 
(v) Where I have reproduced a publication of which I am author, co-author or editor, I have 
indicated in detail which part of the publication was actually written by myself alone and 
have fully referenced such publications. 
 
(vi) This dissertation/thesis does not contain text, graphics or tables copied and pasted from the 
Internet, unless specifically acknowledged, and the source being detailed in the 
dissertation/thesis and in the References sections. 
 













Thank you to my Supervisors, Prof. Koleka Mlisana and Dr Marian Loveday who helped and supported 
me and kept me on the right track throughout this process. A thank you also goes to Sister Lee-Megan 
Larkan from the Greytown TB Facility who always made time to assist me when required. Thanks to 
the Greytown TB Hospital and the NHLS who made it possible for me to conduct this research. Also 
mention must be made to Ebenezer Ogunsakin who assisted me with the statistics. Lastly, thank you to 



































Drug resistant tuberculosis (DR-TB) is a serious public health issue both globally and nationally, with 
South Africa and Kwazulu-Natal, in particular, being among the regions with the highest burden of DR-
TB. Detecting drug resistance and initiating patients onto the appropriate therapy, in the shortest 
possible time, is of utmost importance to the effective management of DR-TB. The development of 
molecular diagnostic techniques allows for more rapid diagnosis of TB, as well as drug resistance, 
leading to earlier diagnosis and subsequent initiation onto appropriate treatment.  
For phenotypic drug susceptibility testing (DST), the laboratory turnaround time is 4 – 6 weeks, thus 
patients are either initiated onto empiric and sometimes inappropriate treatment or have to wait to be 
initiated onto appropriate therapy, remaining untreated and infectious for extended periods of time. The 
introduction of GeneXpert testing revolutionised TB diagnostics as it allowed for diagnosis of TB whilst 
also providing susceptibility results for rifampicin within a few hours. Direct 1st and 2nd line LPA testing 
was included in the DR-TB management algorithm to further reduce the time to treatment initiation of 
multidrug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB).  This also ostensibly 
reduces the amount of time a patient is transmissible for and improves treatment outcomes. This study 
was undertaken to assess the impact of the introduction of the direct 1st and 2nd LPA reflex testing on 
the management of DR-TB in the Umzinyathi District of Kwazulu-Natal. 
 
Methods 
The cohorts before and after the roll-out of direct 1st and 2nd line LPA testing were analysed for patient 
characteristics, diagnostic information, time to appropriate treatment initiation and treatment outcomes. 
Furthermore, the diagnostic tests were compared to ascertain if 1st and 2nd line LPA is comparable to 
phenotypic DST for drug susceptibility testing.  
 
Results 
There were 141 patients included in the 2015/2016 cohort before direct 1st and 2nd LPA was included 
in the algorithm, and 102 patients in the 2017/2018 cohort after its implementation. There was a 
significant decrease between cohort 1 and cohort 2, in the laboratory turnaround time for both 1st line 
LPA, which decreased from 36 days (IQR 23 – 60) to 17 days (IQR 11 – 30), respectively, and 2nd line 
LPA, which compared to phenotypic DST, decreased from 45 (IQR 23 – 67) to 21 days (IQR 12 – 50). 
Time to appropriate treatment initiation was similar across both cohorts for RR- and MDR-TB, from 8 
days (IQR 5 – 13) to 9 days (IQR 7 – 29) in the second for RR-TB, and from  8 days in cohort 1 (IQR 
6 – 20) to 12 days (IQR 6 – 50) in cohort 2 for MTB-TB. The time to appropriate treatment was 
significantly reduced in XDR-TB patients from 267 (IQR 145 – 796) to 62 days (IQR 45 – 182) 
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(p=0.018). Moreover, the treatment outcomes in XDR-TB improved after the roll-out of direct 1st and 
2nd line LPA. Xpert, 1st line and 2nd line LPA performed well compared to phenotypic DST for antibiotic 
resistance detection.  
 
Conclusion 
The laboratory turnaround time and time to appropriate treatment initiation improved after the 
implementation of direct 1st and 2nd line LPA. Despite a delay in initiating therapy after laboratory 
diagnosis, there were positive impacts found regarding treatment outcomes of XDR-TB. Patients were 
initiated on the appropriate treatment, in response to 2nd line LPA results, in the first instance, which 
improved treatment success rates in XDR-TB patients.  
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Mono-resistant-TB Resistance to one first-line anti-TB drug only. 
RR-TB  Resistance to rifampicin, detected using phenotypic or 
genotypic methods, with or without resistance to any other 
anti-TB drugs. 
DR-TB This refers to disease which is resistant to one or more anti-
tuberculosis drugs.  Resistance is determined through 
laboratory confirmation of in vitro resistance to one or more 
anti-tuberculosis drugs.  Drug-resistant TB develops when 
micro-organisms are not killed or inhibited by a specific 
antibiotic due to the selection of naturally occurring resistant 
mutants through inadequate therapy (too few medications, 
insufficient dosing and/or inadequate duration of therapy).   
MDR-TB  A patient with multidrug-resistant TB has a strain of 
bacteriologically proven TB in which the bacilli show in vitro 
resistance to rifampicin and isoniazid, with or without 
resistance to other first line anti-TB drugs. 
Pre-XDR-TB  A patient with bacteriologically proven TB in which the bacilli 
show in vitro resistance to rifampicin, isoniazid and either an 
injectable or a fluoroquinolone.  
XDR-TB  A patient with extensively drug-resistant TB has a strain of 
bacteriologically proven TB in which the bacilli show in vitro 
multidrug-resistant TB together with resistance to any 
fluoroquinolones, plus resistance to one or more the following 
injectable anti-TB drugs:  kanamycin, amikacin, capreomycin. 
Pulmonary TB Any bacteriologically confirmed or clinically diagnosed case 
of TB involving the lung parenchyma or the tracheobronchial 
tree. 
Extrapulmonary TB Any bacteriologically confirmed or clinically diagnosed case 
of TB involving organs other than the lungs. 
 
New patient  Has never been treated for TB or have taken anti-TB drugs for 
less than 1 month. 
Recurrent Has previously been treated for TB and were 
declared cured or treatment completed at the end of their most 
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recent course of treatment and are now diagnosed with a 
recurrent episode of TB (either a true relapse or a new episode 
of TB caused by reinfection). 
Treatment after failure Have previously been treated for TB and whose treatment 
failed at the end of their most recent course of treatment. 
Treatment after loss to follow-up Have previously been treated for TB and were declared lost 
to follow-up at the end of their most recent course of 
treatment. 
PT1 Previously treated with 1st line anti-TB drugs. 
PT2 Previously treated with 2nd line anti-TB drugs.  
DR-TB Cured A patient who has had a DR-TB culture conversion, 
received treatment for a total duration of >9 months, has 
had at least 3 consecutive negative TB cultures during 
continuation phase (at least 30 days apart) and there is 
no evidence of clinical deterioration 
DR-TB Treatment completed A patient who has had DR-TB culture conversion, 
received treatment for >9 months, has less than 3 
consecutive negative TB cultures during continuation 
phase (at least 30 days apart) and there is no evidence of 
clinical deterioration 
Loss to follow up A patient whose treatment was interrupted for two or 
more consecutive months for any reason without 
medical approval 
DR-TB Treatment failure A DR-TB infected patient failed to undergo culture 
conversion by month 4 or two or more of the five 
cultures recorded in the final 6 months of therapy are 
positive, and the patient’s clinical condition is 
deteriorating, or if a clinical decision has been made to 
terminate treatment early or to change the treatment 
regimen by adding more than two medicines due to poor 
clinical and/or radiological response or adverse events. 
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Died A patient who dies from any cause during the course of 
DR-TB treatment 
Transferred out A patient who has been referred from the facility to 
another facility in another district, province or country, 
for whom the treatment outcome is not known 
Moved out A patient who has been referred from the facility to 
another facility in the same district, province or country, 
for whom the treatment outcome is not known. 
Not specified A patient recorded in the DR-TB register who does not 
have the necessary recorded data to enable classification 
of outcome any other category. They may be continuing 
extended treatment due to non-adherence or 
complications. 
Successful outcome Includes: Cured and Treatment completed 
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1. Background and Literature Review 
1.1. Defining the Clinical Problem: The Epidemiology of Tuberculosis 
Globally, there were 10 million new cases of tuberculosis (TB) reported in 2018 (1). Of those, 500 000 
were diagnosed with rifampicin resistant-TB (RR-TB). A further 78% of the RR-TB were multi-drug 
resistant-TB (MDR-TB). In the same period, there were an estimated 1.2 million TB related deaths (1). 
South Africa falls among the 30 high TB burdened countries that account for 87% of all TB cases 
globally (1). South Africa has the third highest number of reported TB cases and the fifth highest 
number of undiagnosed cases, and amongst the highest reported incidence and prevalence of both TB 
and MDR-TB in the world (1). Within South Africa, KwaZulu-Natal has the highest incidence of both 
MDR-TB and extensively-drug resistant TB (XDR-TB) cases (2). 
In 2018, South Africa had 227 999 TB cases, 3.4% of which were new MDR-TB cases (1). According 
to World Health Organization (WHO) statistics, South Africa has a 77% treatment success rate for TB, 
and the incidence of TB decreased by 5% from 2017 to 2018 (1, 3). However, treatment success rates 
decrease with increasing resistance, e.g., MDR-TB and XDR-TB success rates are 54% and 58%, 
respectively, below South Africa’s TB eradication goals (3) (Table 1). In 2018, there were 13 199 
MDR/Rifampicin resistant-TB (RR-TB) and 553 XDR-TB cases. Of these, 9 558 (72%) MDR/RR-TB 
patients were started on treatment compared to 539 (97%) XDR-TB patients (3). In the National 
Strategic Plan on HIV, STIs and TB: 2017-2022 (NSP), targets enabling South Africa to achieve the 
Sustainable Development Goals are set. If the country is not able to increase the number of patients 
diagnosed with MDR- and XDR-TB and improve the current success rates for all TB, these targets will 
not be met. (1, 4). 
 
2016 2017 2018 
Total TB cases 244 053 227 224 227 999 
DR-TB care 
MDR/RR-TB cases 19 073 (7.8%) 15 986 (7.0%) 13 199 (5.8%) 
MDR/RR-TB cases started on treatment 11 192 (59.7%) 10259 (64.2%) 9 558 (72.9%) 
XDR-TB cases 967 (0.4%) 747 (0.3%) 553 (0.2%) 
XDR-TB cases started on treatment 628 (64.9%) 463 (62.0%) 539 (97.5%) 
Treatment 
Success 
New & recurrent cases 81% 82% 77% 




2016 2017 2018 
XDR-TB 27% 48% 58% 
Table 1: Drug resistant tuberculosis incidence and successful treatment outcome rates for South Africa 
in 2016, 2017 and 2018 (1, 3, 5).  
(Definition of Abbreviations: TB=Tuberculosis, DR-TB=drug resistant tuberculosis, RR-TB=rifampicin resistant tuberculosis, MDR-
TB=multi-drug resistant tuberculosis, XDR-TB=extensively drug resistant tuberculosis) 
 
Drug resistant tuberculosis (DR-TB) is a major public health concern due to the high mortality, cost of 
treatment, the chronic and infectious nature of the disease, and risk of transmission to the public 
including the health care workers (6). Thus, the timeous diagnosis of drug resistance and 
commencement of appropriate therapy as soon as possible, is of utmost importance in reducing 
transmission, optimising the chances of treatment success and limiting the development of further drug-
resistance (7).   
In 1996, the National Department of Health (NDoH) of South Africa established the National 
Tuberculosis Programme (NTP) (Table 2). Over the last two decades the NTP has evolved to include 
the integration of TB and human immunodeficiency virus (HIV) services, the management of MDR-
TB and decentralization and community-based care of MDR-TB services (4, 8, 9).  
The Stop TB Strategy was launched by the WHO in 2006 to reduce the burden of TB in alignment with 
global targets. Governments the world over committed to its key principles in the aim of reducing the 
TB burden worldwide (10). In 2007, South Africa introduced the TB infection control programme that 
provided for administrative and environmental controls and the use of personal protective equipment 
during the management of TB in primary health care and community settings (11). In 2008, the WHO 
launched the ‘STOP TB Policy’ which emphasized the role of public health systems in strengthening  
national TB programmes (12). To cement these principles in TB management in South Africa, the 
NDoH updated the National Tuberculosis Management Guidelines in 2014 (13). In 2015, the United 
Nations released the Sustainable Development Goals (SDGs). One of the goals of the SDGs is to have 
a world free of TB, with zero deaths and suffering due to TB by 2030 (14). In an attempt to achieve 
these goals, the “End TB strategy” 90-90-90 targets were introduced. These targets include that 90% of 
all people who need TB treatment are diagnosed and receive the appropriate therapy (including first-
line, second-line and preventative therapy, as required), 90% of all those in key and vulnerable 
populations are diagnosed and receive the appropriate therapy and that a treatment success rate of 90% 
is achieved for all those diagnosed with TB by 2030 (15). In response, South Africa adopted the End 
TB targets as part of the national strategy to address the burden of TB in South Africa (1, 4).  
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In the last decade, a number of bold decisions have been taken by the National Department of Health 
in an attempt to address the burden of TB in the country. These include the introduction of rapid 
diagnostic tests for drug susceptible and DR-TB, new pharmaceuticals for the treatment of MDR- and 
XDR-TB, as well as decentralising the management of MDR-TB to district level hospitals and primary 
health care clinics  in an attempt to provide care and support for patients closer to their homes (13). 
Furthermore, in 2015, South Africa launched a comprehensive TB screening and testing campaign, 
focussing on key vulnerable groups, such as inmates in correctional facilities, mineworkers and children 
(11, 16). 
In 2010, of the 7386 cases of laboratory confirmed MDR-TB, only 5402 (73%) patients started 
treatment for MDR-TB (17). The 27% of patients diagnosed with MDR-TB but never initiated on 
treatment was exacerbated by the length of time taken to receive laboratory results (17, 18). In the delay 
period, many rural patients were lost to the system as they may have died, or remain untreated (17, 18). 
In 2015, a third of all new patients with confirmed TB, as well as those previously treated with TB, 
underwent drug susceptibility testing for rifampicin, whereas the rest were treated based on smear-
positive results alone (6).   
Since the inclusion of the GeneXpert MTB/RIF assay (Cepheid Inc.) (Xpert) platform in the South 
African TB diagnostic and management algorithm, 10,566,489 specimens were processed between 
2011 and 2017. Of those, 10.37% were diagnosed positive for TB and 6.54% of the positive TB 
specimens were RR-TB (19). With the introduction of Xpert, the number of diagnosed RR-TB cases 
increased from 7386 in 2010 to over 10 000 in 2011, and approximately 20 000 in 2015 (17). Despite 
these improvements in DR-TB detection rates, there remains a significant gap between diagnosis and 
initiation of appropriate treatment.  
1st line Line Probe Assay (Hain MTBDRplus) (LPA) was introduced in 2008 to diagnose rifampicin 
(RIF) and isoniazid (INH) resistance. After the introduction of Xpert, it was used to confirm RIF 
resistance and determine INH susceptibility, as Xpert only detects RR. The 1st line LPA was performed 
on culture isolates as per the WHO protocol and national diagnostic algorithm (20), and in 2017 the 2nd 
line LPA, which detects fluoroquinolone and injectables resistance, was introduced to shorten the time 
to the diagnosis of XDR-TB (21). 
 
1997 
Phased implementation of directly observed therapy, short course (DOTS), establishment of demonstration and 
training districts (DTD). 
1999 Introduction of fixed-dose combination drugs Establishment of TB and HIV pilot districts  
2000 MDR-TB guidelines endorsed, establishment of MDR-TB treatment facilities. 
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Four-drug fixed-dose combination tablets introduced  
2001 National Drug Resistance Survey  
2002 
Launch of the Medium-Term Development Plan (MTDP), 2002 - 2005  
Guidelines for isoniazid preventative therapy (IPT) for tuberculin skin test (TST)-positive, HIV-infected 
persons  
2003 
TB declared an emergency and TB crisis plan launched  
Electronic TB register introduced  
2005 Minister of Health signs ‘Declaration of TB as an emergency in AFRO (African regional office) region’  
2006 Development of MDR-TB and XDR-TB action plan  
2007 
Launch of the National TB Strategic Plan 2007 - 2011  
Development of infection control guidelines for TB  
2008 Introduction of 1st line LPA (Hain MTBDRplus) as a rapid test for MDR-TB (performed on culture isolates) 
2009 
‘Health in South Africa’ series published in The Lancet, including recommendations for TB/HIV  
WHO review of the NTP  
2010 
6-month IPT for all HIV-infected persons, regardless of TST status  
Anti-retroviral therapy (ART) for TB patients living with HIV with CD4+ counts <350 cells/μl  
2011 
Introduction of Xpert MTB/Rif as a replacement for sputum smear microscopy  
National HIV/TB campaign  
Management of DR-TB policy guidelines approved  
Decentralised management of MDR-TB introduced  
2012 
SA President signs SADC declaration on ‘TB in the mines’  
ART for all HIV-infected TB patients  
Streptomycin removed from retreatment regimen  
2013 
NDoH guidelines for managing TB/HIV in prisons issued  
IPT for at least 36 months for TST-positive, HIV-infected persons  
National drug resistance survey  
Independent WHO Review of NTP  
2014 Updated National TB Management Guidelines  
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2015 Launch and roll out of mass TB screening programme  
2017 Introduction of direct (performed directly on clinical samples) first and second line reflex testing using LPA  
Table 2: Key Milestones in the South African national Tuberculosis programme 1997 – 2017 (8, 22) 
(Definition of Abbreviations: TB=Tuberculosis, HIV=Human Immunodeficiency virus. DR-TB=drug resistant tuberculosis, RR-
TB=rifampicin resistant tuberculosis, MDR-TB=multi-drug resistant tuberculosis, XDR-TB=extensively drug resistant tuberculosis, 
LPA=Line probe assay, NTP=National Tuberculosis Programme, WHO=World Health Organization) 
 
The management of DR-TB in South Africa is highly dependent on timeous laboratory results and the 
consequent rapid initiation of treatment to prevent further transmission, as well as promote adherence 
to the treatment regimen to reduce resistance development. In July 2017, following the WHO 
recommendation, the National Health Laboratory Service (NHLS) introduced direct sputum testing 
using LPA, for both first and second line anti-TB drugs, for all Xpert MTB positive and RIF resistant 
samples to accelerate DR-TB diagnosis (7, 20). This would ostensibly help to achieve the South African 
DR-TB Policy Guidelines recommendation of treatment initiation within 5 days of diagnosis (23). 
 
1.2. DR-TB Diagnostics in South Africa 
Historically, TB control programmes have relied on passive case finding whereby patients with TB 
symptoms present themselves to primary health care facilities. However, to meet the targets of the End 
TB Strategy, new strategies encouraging active case finding by screening high risk populations through 
community and primary health care facility interventions have been introduced (24).  
Prior to 2011, the primary diagnostic method for TB in South Africa, was smear microscopy, and this 
has since been replaced by Xpert (10). Acid-Fast Bacilli (AFB) smear microscopy is still an important 
part of the management of MDR-TB in South Africa, as it is used to estimate bacillary load in sputum 
and thus identify patients most likely to transmit TB and also used to monitor sputum conversion as an 
indication of whether the patient is responding to treatment. The advantages of smear microscopy are 
that it is inexpensive, does not require advanced infrastructure, which is important in limited resource 
settings, and most importantly yields same day results. The limitations of smear microscopy include its 
decreased sensitivity, especially in patients with a bacillary load of less than 5000 AFB/ml of sputum, 
lower sensitivity in HIV co-infected patients, non-differentiation between various mycobacteria and its 
non-differentiation between live and dead bacilli (25). Furthermore, AFB smear microscopy cannot 
detect drug resistance (13, 25, 26). Despite these limitations, AFB smear microscopy remains a 
component of TB (susceptible and DR-TB) management and treatment monitoring.  
Xpert is an automated, polymerase chain reaction (PCR) diagnostic tool for the simultaneous detection 
of Mycobacterium tuberculosis (MTb) and RR-TB. In 2010, the WHO endorsed Xpert as a replacement 
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for smear microscopy and South Africa adopted this policy change in 2011 (27). The test has a short 
turnaround time (2 hours) and it is specific for MTb (28). Furthermore, it can be used on a variety of 
specimens including cerebrospinal fluid, gastric and lymph node aspirates and tissue. There is less 
opportunity for human error and contamination, as the testing is fully automated within a closed 
cartridge (10). Although the infrastructure and initial technological outlay is expensive, cost-
effectiveness studies have shown that, considering the cost of TB treatment, potential transmission risks 
in untreated and incorrectly treated patients, the cost of the Xpert is justified (29, 30). This diagnostic 
tool, however, is limited to diagnosis and cannot be used in monitoring treatment. A further 
complication of the Xpert is how to manage discordant results between genotypic and phenotypic 
methods, commonly a consequence of genotypic gene expression without phenotypic resistance (31). 
Furthermore, Xpert can only detect RR and thus cannot diagnose MDR-TB and XDR-TB, but it is used 
as a proxy for MDR-TB.  
Although South Africa consumes the highest quantities of Xpert cartridges worldwide, a number of 
health system factors undermine the capacity of Xpert to ensure patients with RR-TB are diagnosed and 
started on effective treatment in the shortest possible time (32). A study performed by McCarthy, et al. 
in 2015 during the scale up of the Xpert protocol, revealed that only 14% smear positive, Xpert negative 
and 32% smear negative HIV-infected individuals had subsequent sputum samples cultured, which 
according to the diagnostic algorithm at the time, should be done for all HIV-positive individuals (33). 
This has implications in TB detection rates, essentially leaving a proportion of the population with a 
high risk of TB untested and possibly unidentified, and therefore untreated.  
Xpert Ultra (Xpert Ultra) was developed to improve the sensitivity of this test in patients who are smear 
negative and co-infected with HIV (34, 35). It was introduced in South Africa in 2017 (36), however, a 
multicentre study that recruited TB infected adults from eight countries, demonstrated that this increase 
in sensitivity resulted in a consequent decrease in specificity (35). Despite the improvements in 
sensitivity, it still only detects RR-TB and thus further testing is required for XDR-TB diagnoses.  
Culture is more sensitive than smear microscopy (able to detect 10 AFB/ml sputum) and is still regarded 
as the gold standard for TB diagnostics. It identifies between mycobacterium species, distinguishes 
between live and dead bacilli and allows for drug susceptibility testing (DST). In high burden countries, 
culture is performed on solid Lowenstein-Jensen (LJ) medium, which although has a higher sensitivity 
that a smear, has an extended incubation time (4 – 6 weeks). For this reason, in 2007, the WHO 
recommended that liquid culture be used as a standard reference for MTb diagnosis and DST (37). 
Liquid culture medium, like the Mycobacteria Growth Indicator Tube system (MGIT; Becton, 
Dickinson), yields results much earlier than solid culture media. Depending on the bacterial burden, a 
culture grown on a liquid medium can yield results within 17 – 20 days. In comparison, a culture grown 
on a solid medium will yield results in 42 days. In addition, a culture grown on a liquid medium will 
have a higher yield of bacteria (29.7%) compared to 22.8% for solid medium. Liquid culture systems 
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can be automated (38, 39), but are expensive and require advanced infrastructure and expertise and can 
take up to 42 days to obtain a result. It also requires higher levels of biosafety (10, 26). Liquid media 
was introduced in South Africa in 2007 after the WHO recommended its use for drug susceptibility 
testing in low and medium income settings (40).  
The Line Probe Assay is a molecular PCR-based diagnostic technique that simultaneously determines 
rifampicin (RIF) and isoniazid (INH) resistance in its first line assay, and fluoroquinolones (FLQ) and 
second line injectables (INJ) in the second line assay. This assay was initially introduced as 1st line only, 
for indirect testing on cultured isolates and therefore delayed MDR-TB confirmation (41). This assay 
is currently approved for testing patient samples directly, thus eliminating the time to wait for culture 
to become positive. The LPA has a better sensitivity than microscopy, between 63% and 100% for 
pulmonary and extrapulmonary cases, respectively, opposed to 46.5 % and 12% respectively for 
microscopy (7) (Table 3). However, the LPA cannot be used for monitoring treatment, because it detects 
DNA, whether from live or dead bacilli, and it requires a high level of laboratory expertise and 
infrastructure (10). The laboratory turnaround time for direct LPA performed on sputum is 24 – 48 
hours, opposed to indirect LPA performed on culture isolates, of which the turnaround time is 4 – 8 
weeks (42, 43). 
Before the introduction of the Xpert in South Africa, drug resistance testing was only conducted on 
patients with TB who were not responding to treatment, had MDR-TB contacts or experienced recurrent 
infections, whereas current protocol dictates Xpert on all suspected TB cases (23). The new algorithm 
for TB diagnostic and management in South Africa follows the WHO recommended guidelines (26). A 
standardised drug resistant TB-treatment regimen is initiated on patients with an Xpert positive and RR-
TB result. As of July 2017, first and second line DR-reflex testing (using 1st and 2nd line LPA) is 
performed directly on patient’s sputum samples to confirm rifampicin resistance and establish any 
further drug resistance (Figure 1 and 2). If further drug resistance is found, the treatment regimen is 
altered accordingly to ensure the patient receives the most appropriate treatment (26, 44). The direct 1st 
and 2nd line LPA detects resistance to first and second line drugs within 5 days (stipulated as 28 days in 
the national guidelines to allow for delays in turnaround times), allowing patients to be initiated on 
appropriate treatment more quickly, thereby reducing transmission time, and ultimately the burden of 
DR-TB (45). Often patients with DR-TB are admitted for 4 – 6 weeks for the initiation period and after 
discharge, return for monthly assessments, which includes monitoring the response to treatment with 
acid-fast bacilli (AFB) smear microscopy and DST culture, documenting the development of adverse 




Figure 1: Xpert based tuberculosis diagnostic algorithm in South Africa 2014 (13) 
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Figure 2: Flow diagram depicting the management of TB in South Africa 2017 (8) 
(Definition of abbreviations: GXP=GeneXpert MTB/RIF assay (Cepheid Inc.), DR=drug resistant, INH=isoniazid, LPA=Line probe assay, 
MDR-TB= multi-drug resistant tuberculosis) 
 
Evaluation of Xpert implementation has shown that, although there have been positive improvements 
in TB diagnosis, the implementation of Xpert did not produce the expected improved treatment 
outcomes due to health system issues (46). One of the assumptions prior to the implementation of Xpert 
was that earlier diagnosis of DR-TB would allow for earlier initiation of appropriate treatment and 
ostensibly reduce transmission. With the introduction of the Xpert there was an increase in the 
proportion of patients diagnosed with DR-TB who were initiated on treatment, from 55% in 2011 to 
63% in 2013. In addition, the median time to treatment initiation decreased from 44 days in 2011 to 22 
days in 2012, but only 10% of newly diagnosed DR-TB cases were initiated within the 5-day national 
target (47). However, a major concern was that over a third (37%) of those diagnosed with RR-TB were 
still not initiated on treatment (46). 
The gap between the number of people diagnosed with RR-TB and those initiated on treatment is known 
as the treatment gap. Prior to the roll-out of Xpert, the reasons for the treatment gap of 38% included 
high pre-treatment mortality, long delays in receiving drug susceptibility results and the need for referral 
to a health facility which could initiate MDR-TB treatment. The impact of the roll-out of Xpert was not 
as expected and failed to reduce the time to treatment as much as was hoped (46). Xpert allowed for 
rapid diagnosis of RR-TB and initiation on MDR-TB treatment much earlier. However, as the diagnosis 
of additional resistance to injectables and fluoroquinolones was still delayed as this required the growth 
of positive cultures to allow for phenotypic 1st and 2nd line DST. This provided a catalyst for NDoH to 
introduce faster second-line diagnosis as this would facilitate more rapid initiation of appropriate 
treatment.  
 
 MTb Detection RIF resistance 
Method Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
AFB Smear (48) 53.0 100 N/A N/A 
Culture 93.5 100 100 100 
Xpert (34) Total 65 98 95 98 
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 MTb Detection RIF resistance 
Method Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Smear positive 83 98   
Smear negative 46 98   
Xpert Ultra (34) 
Total 76 96 95 98 
Smear positive 88 96   
Smear negative 63 96   
LPA (49) 
Total 90 95 88 95 
Smear positive 95 100 94 100 
Smear negative 75 94 73 94 
Table 3: Comparison of the sensitivity and specificity of AFB, Culture, Xpert and Xpert Ultra for the 
detection of MTb and RIF resistance (34, 48-51) 
(Definition of abbreviations: AFB=acid fast bacilli, Xpert=GeneXpert MTB/RIF assay, Xpert Ultra= GeneXpert Ultra MTB/RIF assay, 
LPA=Line probe assay, Mtb=Mycobacterium tuberculosis, RIF=rifampicin) 
 
1.3. Do Molecular Techniques Reduce to the Time to Treatment Initiation? 
A Latvian study demonstrated a reduction in time to treatment initiation from 40 to 7 days for first time 
TB cases in an observational cohort study performed between 2009-2012 after the implementation of 
Xpert (52). In South Africa, Naidoo et al, showed that the introduction of direct sputum testing with 
Xpert reduced the time to MDR-TB treatment commencement from 43 days to 17 days (53). A study 
performed at a specialised TB treatment facility in KwaZulu-Natal, found that the introduction of Xpert 
reduced the time from sputum collection to treatment initiation from 92 days to 20 days (45).  
The success of the implementation of Xpert in reducing the treatment initiation delay informed the 
decision to implement first and second line DR-TB reflex utilizing direct LPA in South Africa. A 
retrospective, cohort study in Delhi, India investigated the impact of the introduction of 1st line LPA, 
performed on culture isolates, on time to treatment initiation of MDR-TB treatment, following the 
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revision of their National Tuberculosis Control Programme in 2011. The median time from diagnosis 
to MDR treatment initiation was significantly reduced from 157 days to 38 days (p=0.001). The study 
also revealed lower losses to follow up during treatment from 39% before LPA implementation to 12% 
after the implementation of LPA (54). A South African study to investigate the impact of the 
implementation of 1st line LPA (performed on culture isolates), as a replacement of conventional 1st line 
DST, on the mean time to treatment, revealed that the mean treatment commencement time significantly 
decreased to 62 days with LPA, compared to 78 days with DST (p=0.045) in a demonstration study 
(55). An operational study further tested the mean treatment commencement times in a rural TB 
hospital, which showed and improvement to 55 days with LPA conducted on isolates, opposed to 80 
days with conventional DST (56). These studies demonstrated that 1st line LPA conducted on culture 
isolates improved the mean time to treatment initiation. A study performed in a high throughput 
laboratory in Cape Town demonstrated that the implementation of LPA (performed on culture isolates 
in this case) reduced the laboratory turnaround time to 3 days (IQR 2 – 5) with LPA, from 45 days (IQR 
27 – 122) with phenotypic DST (p<0.001). The research further showed that the time to reporting of 
2nd line LPA results was 31 days (IQR 13 – 82) (57). 
 
 
Figure 3: Accumulative turnaround time for Culture, DST, LPA, Xpert and AFB microscopy 
(Definition of abbreviations: Mtb=Mycobacterium tuberculosis, LPA=Line probe assay, RR-TB=rifampicin resistant tuberculosis, 
XDR/MDR-TB diagnosis=extensively-/multi-drug resistant tuberculosis, DST=drug susceptibility testing) 
 
As shown in the diagram above (Figure 3), the direct (performed directly from clinical samples, as 
opposed to culture isolates) LPA reduces the time to detecting resistance to both 1st and 2nd line TB 
drugs. This allows for significant reduction in time to drug susceptibility testing so that appropriate 




1.4. Does Reduced Time to Treatment Initiation Affect Treatment Outcomes? 
It was assumed, that by reducing treatment initiation delay and starting treatment sooner, treatment 
outcomes would improve.  
A Russian study compared the impact of a direct LPA-based diagnostic algorithm on time to treatment 
initiation and treatment outcomes for MDR-TB patients, with a culture-based algorithm. The results 
demonstrated a reduction in the time to treatment initiation with the implementation of LPA of 50 days 
(p=<0.001) compared to liquid culture and 66 days (p<0.001) compared to solid culture media. The 
LPA-based algorithm had a 65.2% treatment success rate, opposed to the culture-based algorithm which 
had a success rate of 44.8%. There was also a lower mortality with the LPA-based algorithm group 
(7.6%), as compared to the culture-based algorithm group (15.9%). The LPA cohort showed overall 
more favourable treatment outcomes compared to the culture-based algorithm (p=0.003) (58). 
A study in China investigated whether there was an association between time to treatment initiation and 
treatment outcomes. The results showed that those patients with favourable outcomes were initiated on 
treatment a median time of 172 days after diagnosis, as opposed to those with unfavourable outcomes, 
who were initiated a median of 190 days after diagnosis. In addition, they reported that treatment 
initiated within 60 days of diagnosis were associated with favourable outcomes (odds ratio=2.56, 
95%CI=1.22 – 5.36) (59). 
A South African study assessing the clinical impact of the introduction of Xpert in MDR-TB patients, 
found that although there was significant improvement in the time to treatment initiation, it did not 
translate into more favourable patient outcomes (45). Churchyard et al. found that Xpert did not reduce 
mortality at 6 months, as compared to sputum microscopy, and suggested that better treatment outcomes 
could be obtained by addressing health system issues and improving linkage to care (60).  
A third South African study reported a median time to treatment initiation of 11 (range=0 – 180) days, 
but the reduced time to treatment initiation was not associated with an increase in favourable treatment 
outcomes (p = 0.795) (61).  
As the direct 2nd LPA has only been introduced recently, there is no data as yet available documenting 
whether it impacts on treatment outcomes.  
 
1.5. Comparison of LPA with Phenotypic methods 
A study to assess the correlation between genotypic and phenotypic testing for rifampicin resistance 
was conducted in Haiti (62). In this study 89.5% of the genotypic (Xpert and LPA) results were 
confirmed RIF-resistant by DST. The remaining 10.5% were diagnosed as RIF-resistant by molecular 
methods, but RIF-susceptible by DST. This discrepancy was investigated and it was found that the 
manifestation of the genotypic rpoB mutations did not result in phenotypic expression of rifampicin 
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resistance in every case, as they contained a silent mutation (not phenotypically expressed) (62). These 
silent mutations do not impede the action of rifampicin, as they do not result in structural changes in 
DNA-dependent RNA polymerase (63). Unfortunately, this could result in an incorrect diagnosis of 
MDR-TB (62). A Chinese study suggested that there is an epistatic interaction of mutations relating to 
RIF resistance and strain fitness, resulting in the presence of rpoB mutation. These mutations, whether 
expressed or not, play a role in the increased transmission of DR-TB as they are associated with the 
development of secondary mutations that impact positively on strain fitness (64). 
Research conducted in India compared direct LPA with solid culture DST methods for the diagnosis of 
MDR-TB on culture positive samples. Overall, LPA detected MDR-TB 96% of the time, as compared 
to conventional DST using solid culture. Compared with solid culture, the sensitivity and specificity of 
LPA was 98% and 99% respectively for the detection of RIF-resistance; 92% and 99% respectively for 
INH resistance; 97% and 100% respectively for the detection of MDR-TB. The LPA laboratory 
turnaround time was 48 hours. Thus, LPA proved successful in the early diagnosis of mono-resistance 
to INH and RIF in high-burden countries (65).  
 
2. Research Gap and Questions 
The current literature demonstrates that molecular techniques effectively reduce the time to treatment 
initiation, but only a few studies document a correlation between treatment initiation and treatment 
outcomes. A systematic review published in 2016 stated that there was no published evidence to support 
the assumption that treatment initiation delay in MDR-TB cases leads to poor treatment outcomes (66). 
This review had limitations including the differences between groups of patients, and thus the inability 
to effectively compare them. In addition, differences in treatment outcomes could not be attributed to 
decreased time to treatment initiation. Furthermore, there are other processes and factors that could 
affect both time to treatment initiation and treatment outcomes. From the perspective of the health care 
provider these include health system changes between the periods, improved anti-TB medication and 
decentralisation of TB care. There are also patient-level factors which affect both time to treatment 
initiation and treatment outcomes. These include the accessibility of the health facility, family support 
and household responsibilities. Further research is necessary to compare the impact of 1st and 2nd line 
DR-TB testing on treatment outcomes to exclude the impact of other factors on treatment outcomes.  
It is imperative to discern whether the algorithm is being correctly implemented and if not, what 
challenges are hindering the implementation. In this particular instance, evidence concerning TB 
diagnostics is critical for the development of evidence-based protocols and ultimately to contribute 
positively to reducing the burden of TB (67). This reinforces the need for this study.  
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There is a lack of evidence regarding the effectiveness of existing guidelines, thus the knowledge gap 
needs to be filled with empirical research which demonstrates the effectiveness of public health policies 
(68). This study will investigate the following null hypotheses: 
2.1. There is no significant delay between the diagnosis and appropriate treatment initiation in 
DR-TB infected patients in the Umzinyathi district. A significant delay is defined as > 5days, 
as per the National Guidelines.  
2.2. The delay in the initiation of appropriate treatment is not significantly different after the 
implementation of 1st and 2nd line LPA in DR-TB reflex testing, as compared to the 
appropriate treatment initiation delay before the introduction of 1st and 2nd line LPA in DR-
TB reflex testing. 
2.3. There is no significant improvement in treatment outcomes after the implementation of DR-
reflex testing. 
2.4. There is no significant difference between 1st and 2nd line LPA results and phenotypic DST 
results 
 
3. Aims and Objectives 
The aim of this study was to assess the impact of the introduction of direct 1st and 2nd line DR-TB reflex 
testing on time to diagnosis, time to treatment initiation and treatment outcomes in patients with DR-
TB. 
The objectives of this study are: 
3.1. To document the delay in initiation of appropriate treatment and the treatment outcomes in 
patients with DR-TB before and after the introduction of DR-TB reflex testing. 
3.2. To compare the treatment initiation delay and treatment outcomes before and after the 
introduction of DR-TB reflex testing. 
3.3. Analyse first and second line LPA results and compare these to phenotypic DST results.  
3.4. To document operational challenges associated with the implementation of DR-TB reflex 
testing in routine health services. 
 
4. Contextual Framework 
In this study, we evaluated the introduction of the direct 1st and 2nd line LPA tests in a district hospital 
in a rural district in KwaZulu-Natal to determine the time from sputum collection to laboratory results 
for the 1st and 2nd line LPA tests, whether the algorithm has been effective in such a setting, and the 
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time taken for patients to be initiated onto appropriate treatment. Furthermore, to investigate if patient 
outcomes have significantly improved with the introduction of the 1st and 2nd line LPA. Additionally, 
challenges both at clinic, hospital and laboratory level were explored to thoroughly investigate and 
evaluate the effectiveness of the roll out of this diagnostic program.  
This research has importance in the field of medical microbiology and public health. The study serves 
to assess the value and effectiveness of the roll out of DR-reflex testing protocol in a rural hospital. 
Furthermore, the study explored the challenges experienced with the roll-out. 
By comparing treatment initiation delay and outcomes prior to the implementation of DR-reflex testing 
and after the roll-out, we were able to evaluate whether direct 1st and 2nd line LPA has indeed improved 
time to appropriate treatment and improved patient outcomes.  
























5.1. Study Design 
This study was an observational, retrospective cohort study. 
 
5.2. Setting 
South Africa has a district health system with 52 districts across all 9 provinces. Umzinyathi, one of 
KwaZulu-Natal’s 11 districts, was selected for the study. The estimated population of Umzinyathi is 
555 485, with a TB incidence of 250 per 100 000, MDR-TB prevalence of 26.8 cases per 100 000 and 
an HIV prevalence of 6.7% (21, 24, 69, 70). The DR-TB programme execution and monitoring are well 
implemented with an overall treatment success rate of 89%,death rate of 9.8% and rate of loss to follow-
up of 0.4% in 2017 (71, 72). Greytown hospital, MDR-TB unit, which was decentralized in 2017, started 
treating DR-TB patients from the Umzinyathi district in 2008. 
The study included all patients diagnosed with DR-TB, and initiated onto treatment, at the Greytown 
TB hospital from 1 July 2015 until 30 June 2018. The outcomes of patients were defined as the treatment 
outcome 9 months after treatment was initiated.  
 
5.3. Data Collection and Analysis  
A retrospective record review was performed. Data were collected and analysed to document time taken 
to initiate patients diagnosed with DR-TB on appropriate treatment and treatment outcomes before the 
introduction of direct 1st and 2nd line LPA reflex testing (1 July 2015 – 30 June 2016, referred to as 
cohort 1) and after the introduction of this LPA reflex testing (1 July 2017 – 30 June 2018, referred to 
as cohort 2). 
The 1st and 2nd line LPA results were analysed and compared to phenotypic DST results for both periods 
(1 July 2015 – 30 June 2016 and 1 July 2017 – 30 June 2018), noting that for cohort 1, there was only 
the 1st line LPA, which was performed on culture isolates. The clinical and laboratory challenges 
associated with the introduction of direct DR-TB reflex testing protocol were documented. 
Retrospective data were collected from the laboratory and patient records which were accessed directly 
from the online NHLS TrakCareTM Laboratory Information System and the Electronic Drug-resistant 
TB Register (EDR Web) program. Data were captured into a Microsoft Excel 365 spreadsheet 
(Microsoft Corporation, USA), coded and statistical analysis conducted.  
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The Table 4 below outlines the data that were collected from the EDR, as well as descriptions and 
definitions of the terminology used.  
Information type Analysis Parameter Description 
Patient-level 
Characteristics 
Age Age of the patient at the start of treatment  
Gender  
Medical history 
Type of TB 
Treatment information 
Patient Category 
New – Has never been treated for TB or have taken anti-TB drugs 
for less than 1 month 
Recurrent – Has previously been treated for TB and were 
declared cured or treatment completed at the end of their most 
recent course of treatment, and are now diagnosed with a recurrent 
episode of TB 
TF1 –Treatment after failure of first line drugs: Have previously 
been treated for TB with 1st line anti-TB drugs and 
whose treatment failed at the end of their most recent course of 
treatment. 
TAL – Treatment after loss to follow up 
Previous Drug History 
New Case – Has never been treated for TB or have taken anti-TB 
drugs for less than 1 month. 
PT1 – Previously treated with 1st line anti-TB drugs 
PT2 – Previously treated with 2nd line anti-TB drugs 
Details of TB 
Management 
Date of laboratory diagnosis  





Information type Analysis Parameter Description 
Laboratory Turnaround Time 
Defined as the time taken from sputum sample collection, to the 
availability or finalisation of the results in the laboratory. 
Date of treatment initiation Date that the patient was initiated onto anti-TB therapy 
Time to appropriate treatment 
initiation 
All patients diagnosed with RR-TB on Xpert were, according to 
country guidelines started on standard MDR-TB treatment. When 
further resistance was identified either by phenotypic testing or 
LPA, the treatment regimen would be modified to treatment 
appropriate to the patient’s resistance pattern. 
Thus, the time to appropriate treatment is defined as the time from 
sputum sample collection, to the date of initiation of therapy based 
on the above definition.  
If treatment was further changed due to results of laboratory test, 
the date of last treatment initiation was used as the date of 
appropriate treatment.  
Treatment initiation delay 
Time between availability of laboratory results and initiation of 
treatment  
Date of 1st and 2nd LPA 
sputum sample and result 
 
DR-Reflex (LPA) test results 
First line LPA results 
Second line LPA results 
Drug treatment and any 
changes in treatment 
Appropriate treatment is defined as the treatment effective against 
the patient’s specific resistance pattern i.e. treatment initiated 
after drug susceptibility testing and initiated on MDR/XDR drug 
regimen 
Diagnostic test used as basis 
for treatment initiation 
Defined as the diagnostic test likely to be the motive for which 
treatment was initiated – taken as the diagnostic test result 
available closest to date of treatment start or change. Recorded as 
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Information type Analysis Parameter Description 
clinical indication if no diagnostic test was performed within 30 
days prior to treatment initiation 
Phenotypic testing: DST/ 
culture date of sputum sample 
and results 
 
Comparison of molecular and 
phenotypic laboratory results 





A patient who has had a TB culture conversion, received 
treatment for a total duration of >9 months, has had at least 3 
consecutive negative TB cultures during continuation phase (at 
least 30 days apart) and there is no evidence of clinical 
deterioration 
Treatment completed 
A patient who has had TB culture conversion, received treatment 
for >9 months, has less than 3 consecutive negative TB cultures 
during continuation phase (at least 30 days apart) and there is no 
evidence of clinical deterioration 
Loss to follow up 
A patient whose treatment was interrupted for two or more 
consecutive months for any reason without medical approval 
Treatment failure 
A patient failed to undergo culture conversion by month 4 or two 
or more of the five cultures recorded in the final 6 months of 
therapy are positive, and the patient’s clinical condition is 
deteriorating, or if a clinical decision has been made to terminate 
treatment early or to change the treatment regimen by adding 
more than two medicines due to poor clinical and/or radiological 
response or adverse events. 
Died 




Information type Analysis Parameter Description 
Transferred out 
A patient who has been referred from the facility to another 
facility in another district, province or country, for whom the 
treatment outcome is not known 
Moved out 
A patient who has been referred from the facility to another 
facility in the same district, province or country, for whom the 
treatment outcome is not known. 
Not specified 
A patient recorded in the DR-TB register who does not have the 
necessary recorded data to enable classification of outcome any 
other category. They may be continuing extended treatment due 




Successful outcome Includes: Cured and treatment completed treatment outcomes 
Unsuccessful outcome 
Includes: Died, treatment failed and toss to follow up treatment 
outcomes 
Table 4: Data and definitions thereof included in the study 
(Definition of abbreviations: TB=Tuberculosis, RR-TB=Rifampicin resistant Tuberculosis, MDR-TB=multidrug resistant Tuberculosis, 
XDR-TB=Extensively drug-resistant Tuberculosis, Xpert=GeneXpert MTB/RIF assay, LPA=Line probe assay, DST=Drug susceptibility 
testing) 
 
For the analysis of diagnostics (assessment of the performance of Xpert, 1st line and 2nd line LPA 
compared to phenotypic DST), data were captured from the NHLS TrakCareTM Laboratory Information 
System. This included the results of the diagnostic testing performed, as well as dates of sputum 
collection, dates of test and date of result review for all tests, on all patients, initiated within that period 
 
5.4. Statistical Analysis 
The data were analysed using the SPSS statistics (IBMv25) program.  
Descriptive statistics were used to describe categorical, demographic and clinical characteristics as 
some of the data were not normally distributed, thus nonparametric statistical analysis was applied. A 
p-value of <0.05 was considered significant.  
Logistic regression was used to assess the effect of risk factors on treatment outcomes. 
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Sensitivity, specificity, prevalence and predictive values were calculated to compare the performance 
between diagnostic tests. The Cohens Kappa was used as a measure of agreement between tests and 
interpreted as follows: 
• < 0  Poor agreement 
• 0.0 – 0.20 Slight agreement 
• 0.21 – 0.40 Fair agreement 
• 0.41 – 0.60 Moderate agreement 
• 0.61 – 0.80 Substantial agreement 
• 0.81 – 1.00 Almost perfect agreement (73) 
 
5.4.1. Sample size and statistical power 
Using the G*Power (v3.1.9.2) statistical program, the required sample size for comparing two 
independent groups is 88 in each group. Thus, the sample size in the time period 1 July 2015 to 30 June 
2016 is satisfactory at 141 and the sample size in the time period 1 July 2017 to 30 June 2018 is 102 
which complies with the statistical limitations (Appendix G).  
 
5.4.2. Ethical Considerations 
As the study used retrospective data, patient informed consent was not necessary and ethics approval 
was obtained from the BioMedical Research Ethics Committee of the University of KwaZulu Natal 
BREC Reference number: BE635/18 (74). In addition, approval from KwaZulu-Natal Department of 
Health and Umzinyathi District Health Management Team and permission to extract data from the 
National Health Laboratory Service databases was obtained before the study started. 
To preserve patient anonymity any identifying information (name, ID number, date of birth) was kept 
separately from the patient data and the final database was anonymous. All electronic data was password 












6.1. Participant Characteristics 
Between 1 July 2015 to the 30 June 2016, 141 patients with DR-TB were treated at Greytown MDR-
TB hospital. From the 1 July 2017 to the 30 June 2018, 102 patients were treated. The mean age at 
treatment initiation was 37 years old for both cohorts, (SD = 12.5 and 11.1, respectively). In the 
2015/2016 cohort, 88 (63.1%) new patients were initiated onto DR-TB treatment, compared to 60 
(58.8%) in the 2017/2018 cohort.  
In the 2015/2016 cohort, 21 (14.9%) patients were diagnosed with rifampicin mono-resistance (RMR), 
and 43 (30.5%) were diagnosed with RR-TB with Xpert, but INH resistance was not confirmed. A 
further 65 (46.1%) patients were diagnosed with MDR-TB, 5 (3.5%) had pre-XDR-TB, there was 1 
(0.7%) INH mono-resistant patient and there were 6 (4.3%) patients with XDR-TB. In the 2017/2018 
cohort, 19 (18.6%) of the patients were RMR, 31 (30.4%) were RR with no INH confirmation, 39 
(38.2%) had MDR-TB, 3 (2.9%) had pre-XDR-TB, 1 (1.0%) patient was INH mono-resistant and 9 
(8.8%) patients were diagnosed XDR-TB.  
The baseline characteristics of the study participants are shown in Table 5. The two cohorts were similar 




N (%) N (%) 
Patients initiated onto treatment  N = 141 N = 102  
Mean age at treatment start 37.2 (SD 12.5) 37.5 (SD 11.1) 0.833 
Gender Female patients 73 (51.8%) 64 (62.7%)  
Type of Drug-
resistant TB 
Mono-resistant (INH) 1 (0.7%) 1 (1.0%) 
0.387 
Mono-resistant (RIF) 21 (14.9%) 19 (18.6%) 
RR (INH resistance not confirmed) 43 (30.5%) 31 (30.4%) 
MDR  65 (46.1%) 39 (38.2%) 
Pre-XDR 5 (3.5%) 3 (2.9%) 
XDR 6 (4.3%) 9 (8.8%) 






N (%) N (%) 
Previous Drug 
History 
Previously treated with 1st line drugs 53 (37.6%) 36 (35.3%) 




2015/2016 N= 139 
Pulmonary 136 (97.8%) 97 (95.1%) 
0.685 
Extra-pulmonary 3 (2.2%) 5 (4.9%) 
HIV Status 
2015/2016 N= 140 
HIV Positive 113 (80.7%) 84 (82.4%) 
0.811 
HIV Negative 27 (19.3%) 18 (17.6%) 
Anti-retroviral 
Therapy  
2015/2016 N= 113 
2017/2018 N=84 
On ART 111 (98.2%) 84 (100%) 0.916 
Table 5: Baseline characteristics of study participants for the period 1 July 2015 – 30 June 2016 and 01 
July 2017 – 30 June 2018 
(Definition of abbreviations: INH=isoniazid, RIF=rifampicin, RR=rifampicin resistant, MDR=multi-drug resistant, Pre-XDR=pre-extensively 
drug resistant tuberculosis, XDR=extensively drug resistant tuberculosis, HIV=human immunodeficiency virus, ART=anti-retroviral therapy) 
 
6.2. Time to Diagnosis and Treatment of DR-TB 
6.2.1. Time from Sputum Sample to Laboratory Result and to Treatment Initiation 
As illustrated in Figure 4, the median time to availability of laboratory results from sputum collection 
(laboratory turnaround time) for Xpert was 1.0 day (IQR 0 – 1) for both cohorts (p=0.087). The median 
time to treatment initiation from sputum collection for the patients initiated on the basis of Xpert results, 
was 7 days for both cohorts (IQR 5 – 9 in cohort 1, IQR 5 – 12 in second cohort) (p=0.546).  The 
median time to appropriate treatment initiation from sputum collection for MDR-TB patients was not 
significantly different between the two cohorts; 8 days (IQR 6 – 20) for MDR-TB patients in cohort 1 
and 12 days (IQR 6 – 50) for MDR-TB patients in cohort 2 (p=0.133).  
1st line LPA confirms INH resistance and thus MDR-TB; and there was a significant decrease in the 
laboratory turnaround time for MDR-TB diagnosis from 36.0 days (IQR 23 – 60) in the 2015/2016 
cohort to 17.0 days (IQR 11 – 30) in the 2017/2018 cohort (p=0.019). Furthermore, the time to 
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appropriate MDR-TB therapy was significantly reduced from 41.0 days (IQR 35 – 61) in cohort 1, to 
29 days (IQR 24 – 30) in cohort 2 (p=0.029) (Figure 4).  
In cohort 1, XDR-TB could only be diagnosed based on phenotypic DST, which took a median of 45 
days (IQR 23 – 67) to the availability of laboratory result, and a further 8 days to initiate patients onto 
the appropriate therapy. The introduction of 2nd line LPA in cohort 2, however, reduced the laboratory 
turnaround time for XDR-TB diagnosis to 21 days (IQR 12 – 50) (p=<0.001), and also reduced the 
time to appropriate XDR-TB treatment from collection of sputum specimen, from 53 days (IQR 40 – 
66) in cohort 1, to 35 days (IQR 21 – 50) in cohort 2 (p=0.033). There was, however an increase in the 
delay between the availability of results and the initiation of treatment between cohort 1 and cohort 2, 
from 5 days to 12 days, respectively. 
In cohort 1, all XDR-TB patients were initially diagnosed as having MDR-TB and started on treatment 
within a median of 8 days (IQR 2 – 46). On failing treatment, resistance testing was done, and they 
were shown to have XDR-TB and they were started on appropriate XDR-TB treatment regimens. The 
time to appropriate treatment initiation was taken as the time from the original MDR-TB diagnosis to 
the time of appropriate treatment initiation, as it was only at this point that the patients were diagnosed 
and treated with the appropriate 2nd line anti-TB drugs. Thus, the median time to appropriate treatment 
was 267 days (IQR 145 – 796) for XDR-TB infected patients in the 2015/2016 cohort. In contrast, the 
median time to appropriate XDR-TB treatment in the 2017/2018 cohort was 62 days (IQR 45 – 182). 
Thus, the time to appropriate therapy was reduced by 205 days for XDR-TB patients after the 
introduction of direct 1st and 2nd line LPA (p=0.018).  
Despite laboratory results being available, Figure 4 demonstrates a delay between the laboratory 





Figure 4: Illustrates the time to the availability of laboratory result (laboratory turnaround time) from 
sputum collection for Xpert, 1st & 2nd line LPA and phenotypic DST, compared to the time to 
appropriate treatment initiation from sputum collection for each diagnostic test, as well as the delay 
between the availability of results and treatment initiation (treatment initiation delay).  
(Definition of abbreviations: Xpert= GeneXpert MTB/RIF assay, LPA=line probe assay, DST=drug susceptibility testing) 
6.3. Treatment Outcomes 
Figure 5 demonstrates the distribution of treatment outcomes across both cohorts. Of the 141 
participants in the 2015/2016 cohort, 40 (28.4%) died, 84 (59.4%) were cured, 5 (3.5%) were lost to 
follow up, 2 (1.4%) completed treatment, and in 10 (7.1%) cases, treatment failed. That is, 61.0% were 
successful, opposed to 39.0% unsuccessful outcomes.  
Of the 102 participants in the 2017/2018 cohort, 26 (25.5%) died, 55 (53.9%) were cured, 6 (5.9%) 
were lost to follow up, 3 (2.9%) completed treatment, 1 (1.0%) failed treatment and 11 (10%) were not 
evaluated (Figure 5). That is, in cohort 2, 63.7% of cases reported successful outcomes, and 36.3% had 
unsuccessful outcomes. There was no significant improvement reported in cohort 2 for successful 
outcomes (p=0.656).  
Of the 113 (80.7%) HIV positive patients in cohort 1, 69 (61.1%) had successful treatment outcomes, 
compared to 46 (54.8%) of the 84 (82.4%) HIV positive patients in the cohort 2. The decrease in 


















































Figure 5: Percentage distribution of treatment outcomes for patients with drug resistant Tuberculosis in 
the Umzinyathi district during the 2015/2016 and 2017/2018 cohorts 
 
6.3.1. Comparison of Treatment Outcomes per DR-TB Type 
With regard to MDR-TB, in both cohorts the treatment cure rate was 69.2%. A smaller percentage of 
MDR-TB patients died in the 2017/2018 cohort, 6 (15.3%) compared to the 2015/2016 cohort, where 
14 (21.5%) patients died. There were no successful treatment outcomes for XDR-TB patients in the 
2015/2016 cohort, as all patients’ treatment failed. In comparison, in the 2017/2018 cohort, a half of 
the patients had a successful treatment outcome (p=<0.001). In cohort 2, there was 1 (16.7%) failed 
treatment, 1 (16.7%) patient lost to follow-up and 1 (16.7%) death.  
 
6.3.2. Relationship between Time to Treatment Initiation and Treatment Outcomes 
Figure 6 demonstrates that in both cohorts, the most successful outcome rates occur in patients that have 
been placed on appropriate therapy within 15 days of sputum collection. If both cohorts were combined, 






































Figure 6: Successful treatment outcome rates for both cohorts (2015/2016 and 2017/2018) recorded in 
days to appropriate treatment initiation ranges.  
 
6.3.3. Predictors of Successful Treatment Outcomes 
In univariate analysis, patients with MDR-TB were 5.17 times more likely to have a successful 
treatment outcome (odds ratio (OR)=5.17, 95%CI=1.46 – 18.30, p=0.011) than patients with XDR-TB.  
6.3.1. Changes to Treatment Regimen and its Effect on Treatment Outcomes 
There were 23 (16.3%) treatment regimens that were altered in the 2015/2016 cohort, 95.7% of these 
regimens were altered due to subsequent laboratory tests. Whereas, in the 2017/2018 cohort, of the 18 
(17.6%) treatment regimens that were altered, only 22.2% were changed due to diagnostic testing. The 








































6.4. Comparing Phenotypic DST to Molecular Methods 
6.4.1. Drug Susceptibility Results  
 
Figure 7: Drug susceptibility results across all patients initiated in the periods 1 July 2015 – 30 June 
2016 and 1 July 2017 – 30 June 2018. 










6.4.2. Comparison of Resistance Results across Xpert, LPA and DST 
To assess the performance of Xpert and LPA in detecting antibiotic resistance, pairwise undetected 
results from the phenotypic DST, Xpert, 1st and 2nd line LPA were excluded. Phenotypic DST was used 
as the gold standard.  
For Xpert, 120 results were compared with phenotypic DST for rifampicin (RIF) resistance and the 
Xpert results agreed with phenotypic DST 98.3% of the time, showing only 2 (1.7%) discordant results. 
Xpert had a sensitivity of 99.2% and a positive predictive value (PPV) of 99.2%. Specificity and 
negative predictive value (NPV) could not be calculated as there were no true RIF sensitive patients in 
either cohort. The prevalence of RIF resistance in the study sample was 99.2%. There was a poor 
agreement (Kappa=-0.008, p=0.927) between Xpert and phenotypic DST in detecting RIF resistance, 
but this is because specificity cannot be calculated.  
Xpert and 1st line LPA were compared across 72 tests, where Xpert agreed with 1st line LPA for RIF 
resistance 88.9% of the time. There were 7 discordant Xpert RR results and 1 discordant Xpert RIF 
sensitive result (11.1%). 
First line LPA results were compared with phenotypic DST for RIF resistance in 85 patients, of which 
the prevalence of RIF resistance in the study population was 98.8%. There were no discordant results 
in the dataset for 1st line LPA RR and phenotypic DST RR. There were, however, 2 discordant 1st line 
LPA INH-R results and 1 INH-Sensitive (S) result (3.6%). First line LPA had a sensitivity and 
specificity of 100.0%, as well as PPV and NPV of 100%. There is an almost perfect agreement between 
1st line LPA and phenotypic DST for the detection of RIF resistance (Kappa=1.0, p<0.001). For 
isoniazid (INH) resistance, 1st line LPA was compared to phenotypic DST for 84 patients and reported 
a 64.3% prevalence of INH resistance in the study population. First line LPA had a sensitivity of 98.1% 
and a specificity of 93.3% (PPV=96.4% and NPV=96.6%). 1st line LPA showed an almost perfect 
agreement with phenotypic DST for the detection of INH resistance (Kappa=0.92, p=<0.001).  
2nd line LPA agreed with phenotypic DST 90.7% of the time for FLQ-R, with 4 (9.3%) discordant 
results and agreed with phenotypic DST results, 92.9% of the time for INJ-R, with 3 (7.1%) discordant 
results. Second line LPA was compared to phenotypic DST for fluoroquinolone (FLQ) resistance for 
43 patients and the prevalence of FLQ resistance in the study population was 7.0%. Second line LPA 
has a sensitivity of 100.0% and specificity of 90.0% for detecting FLQ resistance (PPV=42.9% and 
NPV=100.0%). Second line LPA showed moderate agreement with phenotypic DST for the detection 
of FLQ resistance (Kappa=0.56, p<0.001). Second line LPA was further measured against phenotypic 
DST for injectables (INJ) antibiotic resistance in 42 patients. The prevalence of INJ resistance in the 
study population was 11.9%. The sensitivity and specificity of 2nd line LPA was 100.0% and 91.9%, 
respectively (PPV=62.5% and NPV=100.0%). There was a substantial agreement between 2nd line LPA 
and phenotypic DST for the detection of INJ resistance (Kappa=0.73, p<0.001).  
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Therefore, 1st and 2nd line LPA results are not significantly different from phenotypic DST. 
 
6.5. Challenges 
6.5.1. Lack of LPA Testing 
In the 2015/2016 cohort only 13.5% of the patients had 1st line LPA and 2.1% had 2nd line LPA. In the 
2017/2018 cohort there was a dramatic increase in the number of LPAs performed and 88.2% had 1st 
line LPAs performed, and 85.3% had 2nd line LPA. 
 
6.5.1. Inconclusive Results  
Of the 11 1st line LPA tests performed in the 2015/2016 cohort, 1 (9.1%) was inconclusive, whereas in 
the 2017/2018 cohort, of the 254 tests performed, 42 (16.5%) were inconclusive. Of the 792 2nd line 




















7. Discussion  
In South Africa 1st line LPA was introduced in 2008 and 2nd line LPA in 2017, in our study we compared 
the introduction of direct 1st and 2nd line DR-TB reflex testing on time to diagnosis, time to treatment 
initiation and treatment outcomes in two cohorts of patients with DR-TB.cohort 1 was in 2015/2016 
and cohort 2 was 2017/2018. During the 2015/2016 period, patients with RR-TB on Xpert, had a second 
sputum sample collected for culture, and culture positive samples had 1st line LPA done and if resistant, 
phenotypic DST was performed. Whereas, in the 2017/2018 period, patients with RR-TB on Xpert had 
a second sputum sample collected for concurrent 1st and 2nd line direct reflex testing and culture. DR-
TB management and care was centralised in cohort 1, but was decentralised before cohort 2.  
In our comparison, we show that the time to diagnosis decreased. The median time to availability of 
laboratory results from sputum collection (laboratory turnaround time) for Xpert was 1 day for both 
cohorts (p=0.087). There was a noticeable improvement in laboratory turnaround time for 1st line LPA 
from the 2015/2016 cohort, to the 2017/2018 cohort, of 36 days to 17 days, respectively (p=0.019) The 
laboratory turnaround time for phenotypic DST was similar across both cohorts, 53 days and 56 days, 
respectively (p=0.271). Furthermore, there was a significant decrease in time to XDR-TB diagnosis 
from baseline sputum sample (resistance to 2nd line drugs), from 45 days for phenotypic DST in cohort 
1 to 21 days for 2nd line LPA in the cohort 2 (p=0.033).  
In the cohort 1, patients were initially tested with Xpert, with subsequent culture and then 1st line LPA 
performed on positive culture isolates and subsequent phenotypic DST if indicated. 2nd line LPA was 
not available in cohort 1 period. Whereas, in the 2017/2018 cohort, patients were initially tested with 
Xpert, then DST was performed by direct 1st and 2nd line LPA performed on clinical samples. This is 
verified by the fact that there were similar numbers of patients tested with Xpert and phenotypic DST 
in both cohorts, but 1st and 2nd line LPA saw a marked increase in numbers of patients tested in  cohort 
2. This effectively illustrates the change in the diagnostic algorithm to include 1st and 2nd line LPA as a 
reflex test for DR-TB. Furthermore, it is demonstrated that the change in the algorithm impacted the 
laboratory turnaround time for diagnostic tests, specifically 1st and 2nd line LPA.   
Our time to treatment initiation results for XDR-TB patients were consistent with the findings of 
Barnard, et al. in their investigation of 2nd line resistance diagnostics to determine the impact of LPA 
on the laboratory turnaround time. The study found that the time from receipt of sample specimens to 
reporting of 2nd line resistance results was 31 days with LPA, opposed to 45 days with culture-based 
DST. Similarly, our study showed time from sputum sample to availability of laboratory results was 35 
days for 2nd line LPA, compared to 53 days with phenotypic DST (57).  
In our comparison of time to appropriate treatment initiation, the median time to appropriate treatment 
initiation for MDR-TB patients was not significantly different between the two cohorts; 8 days for 
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MDR-TB patients in cohort 1 and 12 days for MDR-TB patients in cohort 2 (p=0.133). For XDR-TB 
patients, however, the time to appropriate treatment was significantly reduced from 267 to 62 days, 
between the two cohorts (p=0.018). However, the time to treatment initiation for patients with XDR-
TB, was further reduced to 35 days with those patients diagnosed with 2nd line LPA. 
A consequence of the implementation of direct testing on clinical samples opposed to culture isolates, 
i.e. the change to the diagnostic algorithm, is availability of results significantly earlier, which supports 
the reasons for changing the diagnostic algorithm. This means that patients can be initiated onto the 
appropriate anti-TB therapy in a much shorter time, and thus be contagious in the community for less 
time. The laboratory turnaround time for 1st and 2nd line LPA is still substantial and this delay could be 
consequent of the higher rates of inconclusive results in cohort 2, as a result of the change in the 
algorithm to include direct testing.   
In the comparison of 1st and 2nd line LPA and phenotypic DST results, it was found that 1st line DST 
showed almost a perfect agreement with phenotypic DST for the detection of both RIF and INH, with 
no discordance found for RIF resistance, and two discordant results for INH resistance. Second line 
LPA showed moderate agreement with phenotypic DST for FLQ resistance, with only 4 discordant 
results. Furthermore, 2nd line LPA demonstrated a substantial agreement with phenotypic DST for INJ 
resistance, with only 3 discordant results. Thus, we can concur that 1st and 2nd line LPA is comparable 
to phenotypic DST for the detection of resistance, and justified it’s use as a faster method for reflex 
testing for DR-TB.  
Unfortunately, the improvement in TB diagnostics is not benefitting patients optimally. Although the 
speed of TB diagnostic tests has increased remarkably, there are still delays in getting the results from 
the laboratory to the health care facility, there are often delays in health care facilities contacting patients 
and it takes time for patients to get to the facility. There was an increase in the time taken between the 
availability of LPA result and treatment initiation in cohort 2. This is a consequence of the problem in 
getting patients to return to the facility for both further testing and treatment. In cohort 1, the algorithm 
dictated that patients were hospitalized during DR-TB care, thus explaining the reduced delay between 
the availability of results and treatment initiation. A number of socio-economic factors delay patients 
return to facilities, including limited transport options, lack of finances and shortage of leave from work. 
It has been shown that increased distance from patients’ homes to health facilities is a significant 
predictor of delayed treatment initiation (75, 76). The study population is from a rural area, which would 
impact on how far patients have to travel to seek healthcare, family support and household 
responsibilities. (75, 76)  
In a study by Jacobson et al, it was observed that the introduction of LPA did reduce the time to 
treatment initiation, but improvements in health system infrastructure were required in order to see the 
greatest impacts from new diagnostics (56). Although my study showed a reduction in time to 
33 
 
appropriate treatment initiation, the full impact of 2nd line LPA was probably not seen in the first year 
of implementation as the implementation of new diagnostics and new algorithms often take some time 
to become embedded into routine practice. 
The treatment outcomes between the two cohorts did not significantly improve, with the successful 
outcome rate increasing from 61.0% in cohort 1, to 63.7% in the second (p=0.763). Although 
Padayatchi, et al. found that there was no significant improvement in treatment outcomes associated 
with reduced time to treatment initiation (77), we, however, did find a 50% improvement in treatment 
outcomes for XDR-TB patients in cohort 2. This improvement in treatment outcomes cannot be 
exclusively attributed to the reduction in time to treatment initiation, as changes to the health system, 
such as decentralisation and improvements in anti-TB drugs, may have contributed to these positive 
changes. 
Furthermore, the results demonstrated that there was no significant difference in successful treatment 
outcomes in HIV positive patients between the two time periods (p=0.763). A study into the 
management of patients requiring both ART and TB drugs, however, suggested that there are 
interactions between antiretroviral and TB medications that compromise concomitant treatment 
implementation in limited resource settings (78), and thus further negating the positive effects on 
outcome of the improved algorithm. The most successful treatment outcomes occurred in patients that 
were initiated onto appropriate treatment within 6 – 15 days after sputum collection. This is ostensibly 
due to the fact that MDR/RR-TB makes up the greatest proportion of DR-TB in the both cohorts, 
diagnosed by Xpert, proven to have a rapid laboratory turnaround time, as a predictor of MDR-TB. 
Thus, patients are initiated onto treatment more quickly, and as the research has shown, this is associated 
with better treatment outcomes. This notion is further supported by evidence of the treatment changes. 
The treatment changes in cohort 1 were primarily based on diagnostic testing, suggesting that the initial 
treatment regimen was not appropriate. Cohort 2 saw fewer treatment changes and those patients that 
did have their regimen altered, were mostly due to adverse reactions to therapy. This indicates that in 
cohort 2, appropriate treatment was initiated in the first instance, and changes were largely made due to 
adverse reactions and not drug resistance development.  
1st and 2nd line LPA proved comparable to phenotypic DST for resistance detection, thus reinforcing 
the decision to use this much faster method for MDR- and XDR-TB diagnosis. The problem, however, 
that arose with direct sputum testing was the increase in inconclusive results. The cause for the higher 
inconclusive results is potentially due to reduced bacillary load in the clinical samples, opposed to 
indirect 1st and 2nd LPA that uses culture isolates. These patients then have to wait for phenotypic DST 
results to become available before commencement of appropriate therapy, thus not taking advantage of 
the faster DST that 1st and 2nd line LPA provides. These results are comparable with literature, as a 
study performed in the Western Cape of South Africa to ascertain the value of direct LPA to predict 2-
month positivity in liquid culture, found 26% of samples were inconclusive using direct LPA (79). 
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Additionally, an Ethiopian study found that of 274 presumptive MDR-TB patients, 30.8% reported 
inconclusive direct LPA results (80). This reinforces the need to improve direct testing LPA protocol.  
8. Limitations 
For this study, data were used from the routine databases, routinely collected by health workers, which 
were, at times, incomplete. In an operational setting, missing data was a challenge, specifically missing 
laboratory results which with the sample size of the two time periods, could possibly skew data. It is 
unclear if these data were missing or whether the diagnostic tests were not carried out. There were 
patient records that did not have Xpert results recorded on the EDR, but only LPA. This reduced the 
number of patients who could be included in the statistical analysis, causing possible bias. In addition 
to missing data, the routine data was at times inaccurately captured. This is a limitation often reported 
in retrospective studies using routine data. Additionally, the small cohort sizes were small and limited 
the analyses that could be done. Further studies including more facilities should be performed to achieve 
this objective. In the Western Cape databases have been linked so that results from the NHLS LIMS 
system are directly imported into the EDR. This would negate human error and ensue the EDR is 
updated with laboratory results timeously. At this time, there is no linkage between the two databases 
in the Umzinyathi district, but this should be a future aim. 
Only patients who were initiated onto treatment were enrolled in the EDR, thus the patients that were 
diagnosed with DR-TB but never treated remain unaccounted for in this study. Further investigation 
into the follow-up of these patients should be done.  
The district researched for this study was purposively selected on the basis of their good TB programme 
implementation and monitoring, consequently this district may not be representative of other districts 
in South Africa. Furthermore, the Umzinyathi district of KwaZulu-Natal is a rural district, thus further 
studies to include urban districts needs to be done in order to validate the results.  
To reduce the time taken for the laboratory to send the results to the public health facility, as well as the 
time taken to contact patients to return to the facility for treatment, an SMS flagging system or 
smartphone application, could be put in place. Thus, the health facility and the patient are 
simultaneously informed that results are available, immediately after the laboratory has released them.  
Furthermore, mobile clinics can be implemented to distribute TB-management at community level to 
remote areas. This will not only aid active case finding, but ensure samples are collected more timeously 
and patients initiated onto treatment as quickly as possible.  
 
9. Conclusion 
This study has demonstrated that the introduction of direct 1st and 2nd line reflex testing in the diagnostic 
algorithm has reduced the laboratory turnaround time for DR-TB. However, the challenges in health 
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systems and processes continue to delay patient initiation on therapy, thus negating the advantages of 
the improved diagnostics.  
In a rural district in KwaZulu-Natal, I have shown that time to appropriate treatment initiation for 
patients with XDR-TB was reduced by the introduction of the 2nd line LPA, and as a consequence there 
were more successful treatment outcomes in these patients.  However, further studies are needed to see 
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Appendix A – Tables  
 






N (%) N (%) 
Placed on treatment based on Xpert 113 (80.1%) 73 (71.6%) 0.832 
Placed on treatment based on LPA 0 (0.0%) 11 (10.8%)  
Placed on treatment based on Phenotypic DST 17 (12.1%) 12 (11.8%) 0.679 
Placed on treatment based on Clinical Indication 11 (7.8%) 6 (5.9%) 0.466 
 
A2: Binary logistic regression to illustrate the predictors of successful treatment outcomes  
 Estimate p-value OR 
95% C.I.for EXP(B) 
Lower Upper 
Age at Treatment Start -.027 .067 .974 .946 1.002 
Gender -.458 .163 .633 .333 1.204 
INH mono 1.234 .453 3.436 .137 86.328 
MDR-TB 1.644 .011 5.174 1.463 18.296 
PreXDR-TB 1.136 .304 3.113 .357 27.123 
RR-TB .862 .172 2.367 .688 8.147 
PT1 .345 .754 1.412 .163 12.203 
PT2 .099 .929 1.104 .127 9.599 
PTB .411 .633 1.509 .279 8.168 
HIV negative .248 .608 1.281 .497 3.301 
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 Estimate p-value OR 
95% C.I.for EXP(B) 
Lower Upper 
Not on Short Regimen 1.017 .035 2.764 1.075 7.106 
Days to Appropriate Treatment 
Initiation 
0.009 .196 1.009 .996 1.022 
Not on BDQ -1.146 .014 .318 .128 .790 
A3: Comparison of Xpert rifampicin resistance results with phenotypic DST 
 
 
1st line LPA RR Result 
Total Sensitive Resistant 
Xpert RR Result 
Sensitive N (% within LPA RR Result) 0 (0.0%) 1 (1.5%) 1 (0.4%) 
Resistant N (% within LPA RR Result) 7 (100%) 64 (98.5%) 71 (98.6%) 
Total N (% within LPA RR Result) 7 (100.0%) 65 (100%) 72 (100%) 
A4: Comparison of Xpert rifampicin resistance results with 1st line LPA rifampicin resistance 
 
 
DST RR Result 
Total 
Sensitive Resistant 
1st line LPA RR Result Sensitive N (% within DST RR Result) 1 (100.0%) 0 (0.0%) 1 (1.2%) 
Resistant N (% within DST RR Result) 0 (0.0%) 84 (100.0%) 84 (98.8%) 
Total N (% within DST RR Result) 1 (100.0%) 84 (100.0%) 85 (100.0%) 






1st line LPA INH-R 
Result 
Sensitive N (% within DST INH Result) 28 (93.3%) 1 (1.9%) 29 (34.5%) 







Total N (% within DST INH Result) 30 (100.0%) 54 (100.0%) 84 (100.0%) 






2nd line LPA FLQ-R 
Sensitive N (% within DST FLQ-R) 36 (64.3%) 0 (0.0%) 36 (61.0%) 
Resistant N (% within DST FLQ-R) 4 (7.1%) 3 (100.0%) 7 (11.9%) 
Uninterpretable N (% within DST FLQ-R) 16 (28.6%) 0 (0.0%) 16 (27.1%) 
Total N (% within DST FLQ-R) 56 (100.0%) 3 (100.0%) 59 (100.0%) 






2nd line LPA INJ-R  
Sensitive N (% within DST INJ-R) 34 (64.2%) 0 (0.0%) 34 (58.6%) 
Resistant N (% within DST INJ-R) 3 (5.7%) 5 (100.0%) 8 (13.8%) 
Uninterpretable N (% within DST INJ-R) 16 (30.2%) 0 (0.0%) 16 (27.6%) 
Total N (% within DST INJ-R) 53 (100.0%) 5 (100.0%) 58 (100.0%) 















Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Oct-19 Nov-19 Dec-19
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Concept Sheet
1 1 1 3
100%
Draft Research Question
2 2 2 2
100%
Scope of Research - Initial 
thesis plan 2 1 2 1
100%
Background
2 6 2 2
100%
Structure of the Study
2 6 2 3
100%
Research Aims & Objectives 
2 1 2 2
100%
Research Methodology
2 1 2 3
100%
Ethical issues
2 6 3 3
100%
Submit Research Proposal
2 3 2 8
100%
Literature Search
3 18 1 8
100%
First Draft of Literature Review
4 6 1 8
100%
Ethics Approval
4 2 8 4
100%
Data Collection Retrospective 
Study Period 5 1 13 6
100%
Data Collection Prorospective 
Study Period 14 1 13 6
100%
Analysis and Interpretation of 
Results 15 3 17 22
100%
First Draft of Findings
16 2 16 19
100%
Second Draft of Findings
17 1 19 21
100%
First Draft of Full thesis
18 1 21 22
100%
Second Draft of Full Thesis
19 1 20 21
100%
Intention to Submit
19 1 19 20
100%
Thesis Submission











Plan Duration Actual Start % Complete Actual (beyond plan)
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Appendix C – GCP Certificates 
A.1 Certificate of successful completion of NIH GCP course 
 
A.2. Certificate of Successful Completeion TREE Introduction to Research Ethics 
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Appendix D – Brief Curriculum Vitae of principal investigator 
Tamara Sneyd 
Bracken Farm, Greytown, 3250 | 084-2082120 | tamarasneyd@gmail.com 
Education 
BACHELOR OF SCIENCE | 2002 | UNIVERSITY OF KWAZULU-NATAL 
· Major: Biomedical Science 
· Related coursework: Genetics and Evolution, Diversity of Life, Chemistry 1A1, Physics in the Life 
Sciences, From Molecules to Organisms, Processes and Structures of Life, Chemistry 1A2, Human Body: 
Form and Function, Biochemistry, Basic Immunology, Environmental Microbiology, Cardiovascular/ 
Respiratory Physiology, Neurophysiology, Protein Structure and Function, Molecular biology, 
Microbiology and Health, Endocrine and Renal Physiology, Gastrointestinal Physiology and Blood, 
Functional Cell Architecture, Comparative Immunology, Environmental Toxicology, Medical Bio-
statistics, Research Project – Virology, Molecular Virology, Bioethics, Principles of Biotechnology, 
Medical Microbiology, Bioenergetics, Neuro-endocrinology, Wound Healing 
· Dean’s Commendation: 2002, 2003, 2004 
· Dean’s List of High Achievers: 2002, 2003, 2004 
· Certificate of Merit in Neuro-endocrinology (First in Class) 
· Graduated with Distinction in Major Subjects 
 
BACHELOR OF SCIENCE HONOURS | 2005 | UNIVERSITY OF PRETORIA 
· Major: Medical Criminalistics 
· Related coursework: Forensic Medicine (Pathology), Ballistics, Anthropology, Odontology, 
Criminalistics, Toxicology, Applied Research Methodology, Biostatistics, Medical Law, Practical 
Component: Medico-legal autopsies, Crime scene attendance, Court case attendance, Laboratory skills, 
Research protocol 
· Graduated with Distinction  
 
Experience 
BUSINESS OWNER | PEN & INK | MAY 2017 - PRESENT 
· Editing and writing business specializing in academic writing, journal articles, as well as news, features 
and copywriting.  
ADMINISTRATOR | UMVOTI TYRES & BATTERIES | JUL 2016 – MAY 2017 
· Bookkeeping and administrative functions 
SHERQ ADMINISTRATOR | MASONITE | NOV 2013 – JUN 2016 
· Implementation and maintenance of the risk management software, Auditing, Document control and 
curatorship.  
NURSERY MANAGER | SUTHERLAND SEEDLINGS | JUNE 2009 – DEC 2012 
· Planting Operations, Establishment and administration of ISO 9001:2008 Quality Management System 
· Research, Nursery Statistics, Establishment of Forestry Clonal and Pine hybrid operations, Customer 
follow up service and Sales Repping, Advertisements 
DAIRY MANAGER | OLIVAR FARM | JUL 2008 – MAY 2009 
· Herd fertility – Oestrus synchronisation and AI, Herd health and maintenance, Basic Veterinary 
Procedures, Milk production and recording, Calf rearing, Heifer management, Pasture management, Feed 
utilisation and management, Vaccination programmes 
ENVIRONMENTAL OFFICER | SAPPI SAICCOR | MAY 2007 – JUN 2008 
· Ambient emissions monitoring and reporting, Air dispersion modelling, Plant optimisation 
SHEQ SUPERINTENDENT | SAPPI SAICCOR | APR 2008 – JUN 2008 
· Uphold SHEQ policies and procedures within the factory including: Fire escape systems, safety 
installations, evacuation programs, hazard identification and risk assessments, non-conformance reporting 
and investigation, root cause analysis and incident investigation, adherence to environmental objectives 
and targets, training issues, ISO documentation and auditing.  
CHEMICAL TECHNOLOGIST | SAPPI SAICCOR | APR 2006 – MAY 2007 





Appendix E – G-power tests for determination of statistical feasibility of sample size 
 
 
Sample size for Pearson’s correlation 
 
 G*Power calculation to determine adequate sample size for the dataset at 95% confidence interval and 
0.05 α. 
Proposed statistical information for comparison of the two groups: 
48 
 
t tests - Means: Difference between two independent means (two groups) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = One 
 Effect size d = 0.5 
 α err prob = 0.05 
 Power (1-β err prob) = 0.95 
 Allocation ratio N2/N1 = 1 
Output: Noncentrality parameter δ = 3.3166248 
 Critical t = 1.6536580 
 Df = 174 
 Sample size group 1 = 88 
 Sample size group 2 = 88 
 Total sample size = 176 
 Actual power = 0.9514254 
 









Appendix F – Budget 
Budget Item Comment Reason for Expense Monthly 1 year 2 years 
Running Expenses 
     
Consumables 
   
  
Internet subscription 
Cell C internet 
subscription R788/m. Half 
will be for Masters work 
Online research and 
communications with 
Supervisors R 394,00 R 4 728,00 R 9 456,00 
Paper 
Ream of paper R56/ream 
and average 1 ream per 
month 
Printing of journal 
articles, research 
materials and R 56,00 R 672,00 R 1 344,00 
Pens 
R12 per pen and average 2 
per month 
Stationary consumables 
R 24,00 R 288,00 R 576,00 
Staples 
R15 per box and average 5 
per year R 15,00 R 75,00 R 150,00 
Files R60 and require 2 per year R 60,00 R 120,00 R 240,00 
Post It Notes 
R80.50 per cube and 
require 4 per year R 80,50 R 322,00 R 644,00 
File Dividers 
R10.00 each and require 
for 4 files R 10,00 R 20,00 R 40,00 
Highlighters 
R79.80 per pack, will need 
2 per year R 79,80 R 159,60 R 319,20 
Small Items of 
Equipment 1TB Portable Hard drive Back up of research R 829,00 R 829,00 R 829,00 
 
Canon printer, scanner and 
fax machine 
Printing and scanning 
as I live in a rural area R 499,00 R 499,00 R 499,00 
Travel Travel Expenses 
Once a month 
supervisor meetings 
300km (Greytown to 
Durban) at AA rate of 
R6.66/km R 1 998,00 R 23 976,00 R 47 952,00 
Cost of 
Photocopying/Printing 
Canon 445 and 446 printer 
cartridges cost R279 and 
R289 respectively replace 
every 2 months. Printing consumables R 568,00 R 3 408,00 R 6 816,00 
Total Costs: 
  
R 4 613,30 R 35 096,60 R 68 865,20 
Proposed budgetary requirements for the study 
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Appendix J – Permission from Greytown TB Hospital 
 
